Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5513673> ?p ?o }
Showing triples 1 to 65 of
65
with 100 triples per page.
- Q5513673 subject Q7336348.
- Q5513673 subject Q7441579.
- Q5513673 subject Q8661589.
- Q5513673 subject Q8790228.
- Q5513673 abstract "Rapastinel (INN) (code name GLYX-13) is an intravenously-administered, selective, weak partial agonist of the glycine site of the NMDA receptor (IA ≈ 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression. It is an amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) which rapidly crosses the blood-brain-barrier, but is not active orally. On March 3, 2014 the U.S. FDA granted Fast Track designation to the development of rapastinel as an adjunctive therapy in treatment-resistant major depressive disorder. As of 2015, the drug has completed phase II clinical development for this indication. Phase III clinical trials were expected to be starting in 2015. By Jan. 29, 2016 Allergan plc. (who acquired Naurex in July 2015) announced that its meanwhile Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. FDA for adjunctive treatment of major depressive disorder.In addition to its antidepressant effects, rapastinel has been shown to enhance memory and learning in both young adult and learning-impaired, aging rat models. It has been shown to increase Schaffer collateral-CA1 long-term potentiation in vitro. In concert with a learning task, rapastinel has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, and dentate gyrus pyramidal neurons under glucose and oxygen-deprived conditions. Additionally, rapastinel has demonstrated antinociceptive activity, which is of particular interest, as both competitive and noncompetitive NMDA receptor antagonists are ataxic at analgesic doses, while rapastinel and other glycine subunit ligands are able to elicit analgesia at sub-ataxic doses.Rapastinel does not actually bind to the glycine site of the NMDA receptor, but rather to a site on the NMDA receptor that allosterically modulates the glycine site. As such, rapastinel is technically a partial negative allosteric modulator of the glycine site of the NMDA receptor, or a functional glycine site partial agonist.".
- Q5513673 atcPrefix "none".
- Q5513673 casNumber "117928-94-6".
- Q5513673 iupacName "(S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide".
- Q5513673 pubchem "14539800".
- Q5513673 thumbnail Rapastinel.svg?width=300.
- Q5513673 wikiPageExternalLink allergan-s-rapastinel-receives-fda-breakthrough-th.
- Q5513673 wikiPageExternalLink glyx-13.
- Q5513673 wikiPageWikiLink Q12140.
- Q5513673 wikiPageWikiLink Q1304270.
- Q5513673 wikiPageWikiLink Q15409359.
- Q5513673 wikiPageWikiLink Q17145461.
- Q5513673 wikiPageWikiLink Q17156864.
- Q5513673 wikiPageWikiLink Q173235.
- Q5513673 wikiPageWikiLink Q18026512.
- Q5513673 wikiPageWikiLink Q1805481.
- Q5513673 wikiPageWikiLink Q18204530.
- Q5513673 wikiPageWikiLink Q18205913.
- Q5513673 wikiPageWikiLink Q18378831.
- Q5513673 wikiPageWikiLink Q20707894.
- Q5513673 wikiPageWikiLink Q21098923.
- Q5513673 wikiPageWikiLink Q2116409.
- Q5513673 wikiPageWikiLink Q213373.
- Q5513673 wikiPageWikiLink Q22079537.
- Q5513673 wikiPageWikiLink Q221681.
- Q5513673 wikiPageWikiLink Q221694.
- Q5513673 wikiPageWikiLink Q2365493.
- Q5513673 wikiPageWikiLink Q2649417.
- Q5513673 wikiPageWikiLink Q285166.
- Q5513673 wikiPageWikiLink Q30612.
- Q5513673 wikiPageWikiLink Q414896.
- Q5513673 wikiPageWikiLink Q42844.
- Q5513673 wikiPageWikiLink Q4914025.
- Q5513673 wikiPageWikiLink Q5425270.
- Q5513673 wikiPageWikiLink Q545787.
- Q5513673 wikiPageWikiLink Q620730.
- Q5513673 wikiPageWikiLink Q640448.
- Q5513673 wikiPageWikiLink Q649817.
- Q5513673 wikiPageWikiLink Q7180990.
- Q5513673 wikiPageWikiLink Q7336348.
- Q5513673 wikiPageWikiLink Q7430916.
- Q5513673 wikiPageWikiLink Q7441579.
- Q5513673 wikiPageWikiLink Q770260.
- Q5513673 wikiPageWikiLink Q7706647.
- Q5513673 wikiPageWikiLink Q7836891.
- Q5513673 wikiPageWikiLink Q824258.
- Q5513673 wikiPageWikiLink Q8661589.
- Q5513673 wikiPageWikiLink Q8790228.
- Q5513673 wikiPageWikiLink Q899107.
- Q5513673 atcPrefix "none".
- Q5513673 casNumber "117928".
- Q5513673 iupacName "-N-[-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[-1-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide".
- Q5513673 pubchem "14539800".
- Q5513673 type ChemicalSubstance.
- Q5513673 type Drug.
- Q5513673 type ChemicalObject.
- Q5513673 type Thing.
- Q5513673 type Q8386.
- Q5513673 comment "Rapastinel (INN) (code name GLYX-13) is an intravenously-administered, selective, weak partial agonist of the glycine site of the NMDA receptor (IA ≈ 25%) which is under development by Naurex as an adjunctive therapy for treatment-resistant depression. It is an amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) which rapidly crosses the blood-brain-barrier, but is not active orally. On March 3, 2014 the U.S.".
- Q5513673 label "Rapastinel".
- Q5513673 depiction Rapastinel.svg.